Respiratory syncytial virus vaccines
AssigneePraxis Biologics, Inc.
InventorsPeter R. Paradiso, Stephen W. Hildreth, Branda T. Hu, Antonia Martin-Gallardo, Rasappa Arumugham, Edward E. Walsh
Life of this patent
Estimating the term…
Abstract
Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion protein or a neutralizing epitope of the G protein.
Claims1
An isolated and substantially pure unglycosylated Respiratory Syncytial Virus G protein having a purity of greater than 75% by weight which binds to a monoclonal antibody, where said monoclonal antibody binds to a neutralizing epitope of Respiratory Syncytial Virus G protein.
Dependencies are inferred from the claim text.